189 related articles for article (PubMed ID: 26778368)
21. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.
Leite KRM; Mitteldorf CATS; Srougi M; Dall'Oglio MF; Antunes AA; Pontes J; Camara-Lopes LH
Ann Diagn Pathol; 2008 Aug; 12(4):260-266. PubMed ID: 18620992
[TBL] [Abstract][Full Text] [Related]
22. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
23. Rare histological patterns of prostatic ductal adenocarcinoma.
Lee TK; Miller JS; Epstein JI
Pathology; 2010 Jun; 42(4):319-24. PubMed ID: 20438402
[TBL] [Abstract][Full Text] [Related]
24. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
25. Ductal adenocarcinoma of the prostate.
Shazer RL; Luthringer D; Agus DB; Gross ME
Clin Adv Hematol Oncol; 2004 Jun; 2(6):393-5; discussion 396. PubMed ID: 16163211
[No Abstract] [Full Text] [Related]
26. PSMA expression is highly homogenous in primary prostate cancer.
Tsourlakis MC; Klein F; Kluth M; Quaas A; Graefen M; Haese A; Simon R; Sauter G; Schlomm T; Minner S
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):449-55. PubMed ID: 26153794
[TBL] [Abstract][Full Text] [Related]
27. Optimizing the diagnosis and management of ductal prostate cancer.
Ranasinghe W; Shapiro DD; Zhang M; Bathala T; Navone N; Thompson TC; Broom B; Aparicio A; Tu SM; Tang C; Davis JW; Pisters L; Chapin BF
Nat Rev Urol; 2021 Jun; 18(6):337-358. PubMed ID: 33824525
[TBL] [Abstract][Full Text] [Related]
28. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
29. GAD1 is a biomarker for benign and malignant prostatic tissue.
Jaraj SJ; Augsten M; Häggarth L; Wester K; Pontén F; Ostman A; Egevad L
Scand J Urol Nephrol; 2011 Feb; 45(1):39-45. PubMed ID: 21091088
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
31. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
32. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
Downes MR; Satturwar S; Trudel D; van der Kwast TH
Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
[TBL] [Abstract][Full Text] [Related]
34. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
Samaratunga H; Duffy D; Yaxley J; Delahunt B
Hum Pathol; 2010 Feb; 41(2):281-5. PubMed ID: 20004936
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
[TBL] [Abstract][Full Text] [Related]
36. Pure prostatic papillary adenocarcinoma with ductal features.
Yamashita S; Inaba Y; Soma F; Katayama Y
Hinyokika Kiyo; 2005 Mar; 51(3):207-9; discussion 210. PubMed ID: 15852679
[TBL] [Abstract][Full Text] [Related]
37. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
38. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
39. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC CANCER, USING NOTI-MICROCHIPS].
Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
